RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

Prostate Cancer Clinical Trial

— Restore  

Official title:

A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02090114
• Other study ID #: J1416
• Secondary ID: NA_000933441R01C
• Status: Completed
• Phase: Phase 2
• Start date: August 25, 2014
• Est. completion date: November 11, 2021

Study information

• Verified date: June 2022
• Source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Single-arm, single site, open label study of the effects of parenteral testosterone followed by enzalutamide, abiraterone or castration-only therapy in men with metastatic CRPC who previously progressed on one of these forms of therapy. The study will enroll four cohorts of patients: men with metastatic CRPC who have progressed on enzalutamide (Cohort A; n=30); men with metastatic CRPC who have progressed on abiraterone acetate (Cohort B; n=30); men with metastatic CRPC who have progressed on first line castration-only therapy (Cohort C; n=30); men with metastatic CRPC with inactivating somatic or germline mutations in ≥2 of the genes TP53, PTEN, or RB1 (Cohort D; n=20).

Description:

The trial will enroll up to 110 patients, 30 for each Cohorts A-C and 20 for Cohort D. Eligible patients will continue on androgen ablative therapy with LHRH agonist (i.e. Zoladex, Trelstar, Eligard or Lupron) if not surgically castrated to suppress endogenous testosterone production. Patients will also receive intramuscular injection with either testosterone cypionate or testosterone enanthate at a dose of 400 mg every 28 days. This dosing scheme was designed to produce rapidly fluctuating serum testosterone levels from the supraphysiologic to the near-castrate range (i.e. Bipolar Androgen Therapy [BAT]). Assessments for response to testosterone will be made approximately every 3 months. Upon displaying evidence of progression, patients will then go on to receive either abiraterone (Cohort B) or enzalutamide (Cohort A), whichever agent they had previously progressed on prior to study enrollment. Patients in Cohort C will remain on LHRH agonist therapy and receive no additional androgen ablative hormonal therapy while those in the mutation-positive Cohort D will receive enzalutamide regardless of prior therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 112
• Est. completion date: November 11, 2021
• Est. primary completion date: November 11, 2021
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Performance status =2

• Age =18 years

• Histologically-confirmed adenocarcinoma of the prostate

• Progressing on continuous androgen ablative therapy (either surgical castration or LHRH agonist).

• Documented castrate level of serum testosterone (<50 ng/dl).

• For Cohorts A and B, patients must have progressed on prior treatment with enzalutamide or abiraterone acetate + prednisone (by PSA criteria or radiographically).

• For castration-only Cohort C, patients must have developed castrate resistant prostate cancer after progressing on first line hormone therapy with either surgical castration or LHRH agonist or LHRH agonist plus an anti-androgen.

• For Cohort D patients must have inactivating somatic or germline mutations in =2 of the genes TP53, PTEN, RB1

• Patients progressing on LHRH agonist plus an anti-androgen as first line therapy must be off anti-androgen for 4 weeks prior to first treatment with testosterone.

• Patients with rising PSA on two successive measurements at least two weeks apart.

• For Cohort A (enzalutamide) and Cohort B (abiraterone acetate):

• Prior treatment with up to 2 additional second line hormone therapies, including ketoconazole is allowed.

• Patients who have progressed on both enzalutamide and abiraterone acetate are eligible and post-BAT will be retreated with the last second line agent they had received (e.g. patient receiving abiraterone then enzalutamide would receive retreatment with enzalutamide post-BAT).

• Patients must be withdrawn from enzalutamide or abiraterone acetate for = 4 weeks and have documented PSA increase after the withdrawal period.

• Patients receiving prednisone in conjunction with abiraterone acetate must be weaned off prednisone prior to starting BAT.

• For Cohort C (castration-only):

• Patients must continue on castrating therapy throughout BAT treatment.

• No prior second line hormone treatment with flutamide, bicalutamide, nilutamide, enzalutamide, abiraterone, ketoconazole, ARN-509 or other investigational androgen ablative therapies is permitted for Cohort C.

• For Cohort D (mutation cohort):

• Patients must continue on castrating therapy throughout BAT treatment.

• Treatment with first-generation hormonal therapy (i.e. flutamide, bicalutamide, nilutamide), is allowed

• Patient must have received at least one and not more than two second generation hormone therapies (i.e. enzalutamide, abiraterone, apalutamide).

• For Cohorts A-D, prior docetaxel for hormone-sensitive prostate cancer is permitted if = 6 doses were given in conjunction with first-line androgen deprivation therapy and >12 months since last dose of docetaxel

• For Cohort D, one line of prior chemotherapy with docetaxel or cabazitaxel for metastatic castrate resistant prostate cancer is allowed

• Acceptable liver function:

• Bilirubin < 2.5 times institutional upper limit of normal (ULN)

• AST (SGOT) and ALT (SGPT) < 2.5 times ULN

• Acceptable renal function:

-- Serum creatinine < 2.5 times ULN, OR

• Acceptable hematologic status:

• Absolute neutrophil count (ANC) = 1500 cells/mm3 (1.5 ×109/L)

• Platelet count = 100,000 platelet/mm3 (100 ×109/L)

• Hemoglobin = 9 g/dL.

• At least 4 weeks since prior surgery with full recovery (no persistent toxicity = Grade 1).

• Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

• Pain due to metastatic prostate cancer requiring opioid analgesics.

• >5 sites of visceral disease in lung or liver (nonspecific lung nodules =1 cm in diameter are permitted).

• Prior treatment with docetaxel or cabazitaxel for metastatic castration-resistant prostate cancer is prohibited.

• Prior treatment with one line of chemotherapy for metastatic castration-resistant prostate cancer is allowed for Cohort D

• Requires urinary catheterization for voiding due to obstruction secondary to prostatic enlargement thought to be due to prostate cancer or benign prostatic hyperplasia

• Evidence of disease in sites or extent that, in the opinion of the investigator, would put the patient at risk from therapy with testosterone (e.g. femoral metastases with concern over fracture risk, spinal metastases with concern over spinal cord compression, lymph node disease with concern for ureteral obstruction).

• Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study.

• Active uncontrolled infection, including known history of AIDS or hepatitis B or C.

• Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule.

• Prior history of a thromboembolic event within the last two years and not currently on systemic anticoagulation.

• Hematocrit >50%, untreated severe obstructive sleep apnea, uncontrolled or poorly controlled heart failure [per Endocrine Society Clinical Practice Guidelines (67)].

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Testosterone cypionate
DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
• Testosterone Enanthate
Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
• Abiraterone acetate
Abiraterone is an inhibitor of CYP17 (17a-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
• Enzalutamide
XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.

Locations

Country	Name	City	State
United States	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Baltimore	Maryland
United States	Sibley Memorial Hospital	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Markowski MC, Wang H, Sullivan R, Rifkind I, Sinibaldi V, Schweizer MT, Teply BA, Ngomba N, Fu W, Carducci MA, Paller CJ, Marshall CH, Eisenberger MA, Luo J, Antonarakis ES, Denmeade SR. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy — View Citation

Sena LA, Wang H, Lim ScM SJ, Rifkind I, Ngomba N, Isaacs JT, Luo J, Pratz C, Sinibaldi V, Carducci MA, Paller CJ, Eisenberger MA, Markowski MC, Antonarakis ES, Denmeade SR. Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subseq — View Citation

Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeade SR. Bipolar androgen therapy in men — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy (BAT)	Number of participants with =50% PSA reduction from pre-BAT baseline level	up to 18 months
Primary	PSA Response to Enzalutamide or Abiraterone Acetate Post Bipolar Androgen Therapy	Number of participants with =50% PSA reduction after enzalutamide or abiraterone acetate post-BAT from baseline	up to 24 months
Secondary	PSA Progression on Enzalutamide or Abiraterone Acetate or Castrate Levels Post-BAT	Time to PSA progression on enzalutamide or abiraterone acetate or return to castrate levels of testosterone post-BAT, defined as the time from the date of re-initiation of enzalutamide or abiraterone acetate or castration-only therapy to the date of the PSA measurement when it shows an increase by =25% above the nadir value that occurred following re-initiation of enzalutamide or abiraterone acetate or castration-only therapy and confirmed by a repeat PSA 4 weeks later (PCWG2).	up to 18 months
Secondary	PSA Progression on BAT (Bipolar Androgen Therapy )	Time to PSA progression on BAT. Time to PSA progression on BAT is defined as the time from the date of initial dose of Testosterone to the date of the PSA measurement when it shows an =25% increase above the nadir value and confirmed by a repeat PSA 4 weeks later (PCWG2 criteria) during the treatment with BAT.	up to 18 months
Secondary	Disease Response as Defined by RECIST 1.1 (Soft Tissue Lesions) and PCWG2 Criteria (Bone Lesions)	Number of participants with complete or partial response post-BAT as defined by RECIST 1.1 (for soft tissue lesions) and PCWG2 criteria (for bone disease), or return to castration-only post-BAT.	up to 18 months
Secondary	Initiation of Docetaxel Chemotherapy	Time to initiation of docetaxel chemotherapy	up to 18 months
Secondary	Quality of Life (QoL) as Assessed by FACIT-F Score	Functional Assessment of Chronic Illness Therapy, Fatigue Subscale (FACIT-F) assesses Fatigue with a total score range of 0-52, with a higher score reflecting better QoL.	up to 18 months
Secondary	Safety and Tolerability as Assessed by Number of Participants With Adverse Events	Number of participants who experience adverse events, as defined by NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0.	18 months
Secondary	Quality of Life (QoL) as Assessed by RANDSF-36	RAND 36-Item Short Form (RANDSF-36) assesses physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, general health perceptions, and perceived change in health with a total score range of 0-100. The total score from all of the questions answered is divided by the total number of the questions answered yielding a global score from 0-100, with a higher score reflecting a better QoL.	up to 18 months
Secondary	Quality of Life (QoL) as Assessed by BPI	Brief Pain Inventory (BPI) assesses the severity of pain and its impact on functioning with scales ranging from 0-10, with a higher score indicating a higher level of pain.	up to 18 months
Secondary	Quality of Life (QoL) as Assessed by IIEF	International Index of Erectile Function (IIEF-5) is a diagnostic tool for erectile dysfunction, with a total score range of 5-25, with the lowest score indicating a higher degree of dysfunction.	up to 18 months
Secondary	Quality of Life (QoL) as Assessed by PANAS	Positive and Negative Affect Schedule (PANAS) is a self-report measure that is made up of two mood scales, one measuring positive affect and the other measuring negative affect, with a total score range from 10-50 with a higher score on the positive scale indicating greater levels of positive affect and a lower score on the negative scale indicating less of a negative affect.	up to 18 months